{"entity":{"id":"nct05948475","kind":"trial","name":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","aka":[],"tldr":"A phase 3 trial of Tinengotinib in biliary tract cancer, run by TransThera Sciences (Nanjing), Inc., active and no longer recruiting.","summary":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma is a phase 3 interventional study registered as NCT05948475 by TransThera Sciences (Nanjing), Inc., with 200 participants enrolled, started 2023-12-20 and due to reach its primary completion in 2026-12. Interventions recorded: Tinengotinib 8 mg, Tinengotinib 10 mg and Physician's Choice.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05948475","url":"https://clinicaltrials.gov/study/NCT05948475"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["tinengotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05948475","phase":"3","setting":"A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma","sponsor":"TransThera Sciences (Nanjing), Inc.","enrolled":200,"outcomes":[]},"route":"/trials/nct05948475/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"drug":[{"id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/"}]}}